Epidemiologic evidence suggests diabetic men have a slightly lower prostate cancer risk than nondiabetic men. We examined this association in a prospective cohort study of 35 239 men, 50-76 years old, in Washington State who completed a baseline questionnaire between 2000 and 2002. Incident prostate cancers as of 31 December 2004 were identified through the SEER registry. Diabetic men had a slightly lower risk of prostate cancer than non-diabetic men (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.64-1.07). Insulin users overall and insulin users with diabetic complications had decreased risks, compared to non-diabetic men (HR 0.49, 95% CI 0.26-0.92) and (HR 0.36, 95% CI 0.15-0.87), respectively. Oral medication use for diabetes was not associated with prostate cancer. Insulin is likely a marker of severity of diabetes. Future studies of this association should consider diabetes type, treatment, severity, complications and biomarkers.
Introduction
Epidemiologic evidence suggests that diabetic men have a slightly lower risk of prostate cancer than non-diabetic men. [1] [2] [3] [4] [5] [6] [7] A meta-analysis of 14 studies published before 2003 found a small but significant decreased risk (relative risk 0.91, 95% confidence interval (CI) 0.88-0.94). 6 Of the 14 studies in the meta-analysis, two found significantly decreased risk, six found non-significantly decreased risk and none reported a significant positive association. 6 Four of six studies published subsequently [3] [4] [5] [7] [8] [9] also reported a significantly decreased risk of prostate cancer among diabetic men, with approximately a 30-40% reduction in risk. [3] [4] [5] 7 Although there appears to be a growing consensus based on epidemiologic studies that diabetes is associated with a decreased risk of prostate cancer, both the meta-analysis and individual studies of this association leave many questions unanswered. In particular, most studies, including the meta-analysis, only addressed diabetes as a single, uniform condition which could be either present or absent. Diabetes is actually a heterogeneous disease with respect to its physiology, treatment and complications, and the risk of prostate cancer may vary based on these factors. Overall, only two individual studies have addressed how this association may vary by diabetes treatment, with results suggesting that risk is lowest among men who use insulin. 7, 10 Additionally, only one prior study addressed microvascular complications in diabetic men, 2 while another addressed predominantly macrovascular complications, both suggesting these complications are associated with decreased risk. 5 Several mechanisms have been proposed to explain the association between diabetes and decreased prostate cancer risk. Diabetic men typically have lower levels of testosterone and insulin-like growth factor-1 (IGF-1) than non-diabetic men, 11, 12 and both these hormones stimulate prostate cell growth. [11] [12] [13] Alterations in other growth factors, including leptin, insulin, transforming growth factor beta, vascular endothelial growth factor and tumor necrosis factor-alpha [13] [14] [15] may also help explain this association. Taken as a whole, these varied mechanisms suggest a complex array of factors influencing the association between diabetes and prostate cancer. This leaves open the possibility that men with diabetes may have differing profiles of prostate cancer risk, depending on how the disease, its treatment, and its complications are associated with these various mechanisms.
In this study, we examined the association between diabetes and prostate cancer risk in 35 239 men participating in a prospective cohort study in western Washington. Additionally, we identified how this association varies according to treatment for diabetes, diabetic complications and prostate cancer tumor features. Understanding these associations may help elucidate the etiology of this common cancer.
Materials and methods
Study design and selection of study participants A prospective cohort design was used to examine the relationship between diabetes and prostate cancer risk. Study participants are members of the VITamins And Lifestyle (VITAL) study, a cohort of 77 738 men and women between the ages of 50 and 76 years living in the Puget Sound area of western Washington. Recruitment for the cohort occurred by mail between October 2000 and December 2002, using names purchased from a commercial mailing list. Further details of study methods are given in White et al. 16 Among eligible men, the response rate was 20.6%, for a total of 37 382 participants. Of these, 2141 men who reported a history of prostate cancer on the baseline questionnaire or who left that section or the diabetes section of the questionnaire blank were excluded, as were two men subsequently diagnosed with in situ prostate cancer, yielding a total of 35 239 men for this analysis. This project was reviewed and approved by the Fred Hutchinson Cancer Research Center Institutional Review Board.
Baseline data collection
Baseline data for the VITAL study were obtained from a 24-page, self-administered questionnaire that included items on medical history, physical activity, personal characteristics, diet and cancer risk factors. Subjects were asked about use of insulin and/or 'pills for diabetes or to lower blood sugar' over the past 2 weeks. Men were classified as: non-diabetic if they did not report medication use for diabetes, diabetic using only oral medications or diabetic using any insulin (with or without concurrent use of oral medications). Macrovascular diabetic complications were defined as coronary artery disease (including history of heart attack, coronary bypass surgery, angioplasty and/or physician-diagnosed angina) and/or stroke. Microvascular diabetic complications were defined as self-reported physician-diagnosed kidney disease (ever/never) and/or neuropathy ('numbness in fingers or feet' within the year before baseline).
Other information collected at baseline included: history of prostate-specific antigen (PSA) testing within 2 years before baseline, physician-diagnosed benign prostatic hyperplasia (enlarged prostate), ever having a prostate biopsy, current use of medications commonly prescribed for enlarged prostate (finasteride, terazosin, doxazosin or tamsulosin), first-degree family history of prostate and other cancers, body mass index, level of physical activity and energy intake. With regard to tumor characteristics, SEER summary stage was categorized as local or regional/distant. Gleason score and was categorized as 2-6 and 7-10, corresponding to well-or moderately differentiated cancers and poorly differentiated cancers, respectively. As SEER only implemented this coding scheme in 2003, we reabstracted Gleason scores from the original SEER reports for cancers diagnosed from 2000-2002.
Statistical analyses
Unconditional logistic regression models were used to estimate odds ratios (ORs) for the association between medical and lifestyle characteristics and diabetes, with adjustment for age as a continuous variable. Cox proportional hazard models were used to estimate the hazard ratios for prostate cancer associated with diabetes. Age was treated as the time variable, with left truncation for age at baseline. The hazard ratios can therefore be interpreted as the instantaneous risk ratio computed at each age and averaged over all ages. The proportional hazards assumption of a constant risk ratio over all ages was not statistically violated.
The censored date for each subject was the earliest date of: death (3.9%), move out of the 13 county catchment area of the SEER registry (3.0%), or 31 December 2004. Deaths were ascertained by linkage to Washington State death files. Moves out of area were identified by linkage to the National Change of Address System and by follow-up letters and phone calls.
All statistical models were adjusted for report of PSA testing within 2 years before baseline. No other variables shown in Table 1 altered the age-and PSA-adjusted hazard ratios to an important degree and therefore these variables were not included in the final Cox models. Models were also stratified by PSA testing, age and tumor features. 
Results
In comparison to men without diabetes, men with diabetes were more likely to be older, not married, less educated, non-Caucasian and to have lower income (Table 1) . Diabetic men were less likely to have had a prior prostate biopsy, enlarged prostate or a first-degree family history of prostate cancer, and more likely to have kidney disease, neuropathy, coronary artery disease and history of stroke, and to use medicines for high blood pressure or high cholesterol. Diabetic men also reported higher body mass index, lower physical activity and lower caloric intake compared to non-diabetic men. The prevalence of diabetes at baseline was 8.2%, with 6.0% taking only oral medications to control their blood sugar and 2.2% using any insulin (Table 2) .
Diabetes treatment and prostate cancer risk CM Velicer et al Overall, diabetic men had a small, nonsignificant decreased risk of being diagnosed with prostate cancer compared to non-diabetic men (hazard ratio (HR) 0.83, CI 0.64-1.07), after adjustment for age and PSA (Table 2) . Men taking only oral medications for diabetes were not at decreased risk of prostate cancer (HR 0.94, CI 0.71-1.24), whereas men taking insulin had a 51% decreased risk of prostate cancer in comparison to non-diabetic men (HR 0.49, CI 0.26-0.92). Diabetic men with microvascular (but not macrovascular) complications were at decreased risk (HR 0.62, CI 0.39-0.98), compared to non-diabetic men. Insulin use among men with any complications was associated with further decreased risk (HR 0.36, CI 0.15-0.87), compared to non-diabetic men.
When models of the association between diabetes treatment and prostate cancer were stratified by a number of factors, the decreased risk remained greater for insulin use than for oral medications, as follows: had prior PSA test (HR for prostate cancer among men using insulin vs men without diabetes: 0. 
Discussion
In our cohort of 35 239 men in western Washington State, we found a 17% decreased risk of prostate cancer among diabetic men, compared to non-diabetic men. Although this result was not statistically significant, this decrease is consistent with (although slightly larger than) results from a meta-analysis of 14 studies (RR 0.91, CI 0.86-0.96). 6 We found that men with diabetes who used insulin had a 51% decreased risk of prostate cancer, With the following exception, o5% of data were missing and there was o1% difference in missing data between diabetic and non-diabetic men for any given characteristic: income (15.5% missing for non-diabetic men, 16.3% missing for diabetic men). b Coronary artery disease defined as history of heart attack, coronary bypass surgery, angioplasty or physician-diagnosed angina. c Level of physical activity over 10-year period before baseline, calculated as average met-hours per week, based on 1-page recreational activity section of the baseline questionnaire. d Energy intake estimated from food frequency section of baseline questionnaire, which asked about frequency of intake and portion size of 120 foods over the 1-year period before baseline.
Diabetes treatment and prostate cancer risk CM Velicer et al compared to men without diabetes (HR 0.49, CI 0.26-0.92). These findings are highly consistent with a recent nested case-control study using the General Practice Research Database in the UK, which reported an OR of 0.49 (95% CI 0.26-0.90) for the association between insulin use among diabetic men and prostate cancer, compared to non-diabetic men. 7 A hospital-based casecontrol study in New York City also reported an association of similar magnitude. 10 We found no association between use of oral medications for diabetes and prostate cancer risk (HR 0.94, 95% CI 0.71-1.24), compared to subjects without diabetes. In the UK study, use of sulfonylureas was associated with a decreased risk (OR 0.60, CI 0.42-0.85), whereas no association was found for metformin use (OR 1.16, 0.63-2.14). 7 Although we cannot rule out the possibility of independent associations between diabetes medications and prostate cancer risk, it seems more likely that type of diabetes medication is a marker for severity of diabetes, reflecting underlying physiologic differences between diabetic men who use insulin, who typically have more advanced disease, and those who do not. For example, although men with insulin-resistant type 2 diabetes may initially have increased levels of endogenous insulin, IGF-1 and leptin, as the disease progresses to insulin deficiency (the stage where insulin may be added as a therapy), levels of these factors decrease. 10, 17, 18 Insulin and IGF-1 may be involved in prostate cancer development through stimulating cell growth and proliferation. 11, 15 Other factors, such as circulating leptin, have also been implicated in the development and progression of prostate cancer. 19 Diabetic men with macrovascular complications (coronary artery disease and/or stroke) were not at decreased risk of prostate cancer compared to nondiabetic men (HR 0.88, CI 0.58-1.09). This finding is not consistent with the one prior study of predominantly macrovascular complications, which found that risk was significantly decreased by 39%. 5 However, it is consistent with some reports that low IGF binding protein-1 (and thus high bioavailability of IGF-1, which could increase prostate cancer risk) is associated with increased cardiovascular risk in individuals with type 2 diabetes and other populations. [20] [21] [22] Diabetic men with microvascular complications had a decreased risk of prostate cancer (HR 0.62, CI 0.39-0.98), compared to non-diabetic men. This finding is consistent with the one other study of microvascular complications 2 and with studies suggesting that decreased IGF-1 is associated with neuropathy. 11, 14 The decreased risk of prostate cancer associated with use of insulin was independent of PSA testing status, One interesting ancillary finding of this study is that diabetic men were less likely to have a family history of prostate cancer (Table 1) . This association could be reflective of a familial tendency toward increased risk of diabetes but reduced risk of prostate cancer, possibly through genetic and/or lifestyle factors. It is unlikely that obesity, the lifestyle factor most strongly associated with diabetes, is the reason for this association, because adjustment for obesity did not alter the association between diabetes and prostate cancer in our sample. Also, we found no association between diabetes and family history of other cancers, which suggests that recall bias is not the reason for the observed association between diabetes and family history of prostate cancer. Our finding is consistent with a study suggesting that a polymorphism in the IGF-1 gene is associated with both low IGF-1 concentrations and an increased risk of type 2 diabetes. 23 Our study had several strengths, including a large sample size, the prospective design, the ability to assess risk associated with both diabetes treatment and some diabetic complications, and the ability to control for prior PSA testing as well as a large number of other potential confounding factors. Additionally, the observed number of prostate cancer cases was greater than the expected number for our cohort, based on the number and age distribution of this cohort and SEER rates. Therefore, we believe our linkage methods, coupled with the highly complete CSS cancer registry, were successful in obtaining nearly complete case ascertainment.
A limitation of this study is that diabetes and its complications were ascertained from self-report. Thus, it is possible that misclassification of these factors could have led to bias in our risk estimates. Additionally, our measure of microvascular complications did not include retinopathy, and neuropathy was defined as selfreported 'numbness in fingers or feet' at baseline, which may also be subject to misclassification. Like many prior studies, we lacked data on type of diabetes, duration of diabetes history, history of treatment for diabetes and level of glycemic control (which could influence IGF levels). 17, 24 It is likely that most insulin users in our study were men with advanced type 2 diabetes, since type 2 diabetes is much more common than type 1 diabetes. 25 Also, approximately 33% of diabetes cases are undiagnosed, 25 and therefore, our reference group likely included undiagnosed diabetic men, men who were diagnosed with less severe type 2 diabetes and treated only with lifestyle measures, and men with mild type 2 diabetes who were noncompliant with their prescription instructions. It is unclear how our results would have differed if these individuals were excluded from the reference group. However, given that the only prior study to examine this question found no difference in prostate cancer risk between men with untreated diabetes and men without diabetes, 7 it seems unlikely that exclusion of men with untreated diabetes from our reference group would have substantially altered our findings.
As data were not collected about specific classes of oral medications used for diabetes, we were unable to evaluate associations between use of specific medication classes and altered prostate cancer risk. Results from one study suggest that the thiazolidinediones, often used to treat diabetes, may slow prostate growth in subjects with advanced cancer. 26 Another study observed that different classes of oral medications, in this case metformin compared to the sulfonylureas, had widely differing associations with prostate cancer risk. 7 A possible explanation for the null findings we observed for oral medications is that different types of oral medications have opposite effects on prostate cancer risk.
Other limitations of this study included its primarily Caucasian population, which may limit generalizability of our findings, and limited statistical power for some subanalyses of diabetic complications and cancer grade and stage. Additionally, some men may have had asymptomatic, undiagnosed prostate cancer; their inclusion in the study as a 'non-case' would likely obscure a potential association between diabetes and prostate cancer risk. Finally, residual confounding by factors that were measured imperfectly, or confounding by unmeasured factors, cannot be ruled out.
In summary, in the VITAL cohort, diabetic men who used insulin or who had microvascular complications (predominantly neuropathy) had a lower risk of prostate cancer than non-diabetic men. Our findings suggest that the association between diabetes and decreased prostate cancer risk may be limited to those with the most severe diabetes. Although it seems most likely that insulin use in this study is serving as a marker for duration and/or severity of diabetes, our results are also consistent with the possibility that insulin use is independently associated with decreased prostate cancer risk. These results highlight the need for continuing research into the relationship between prostate cancer and diabetes, taking into account diabetes type, treatment, severity, complications and biomarkers of potential mechanistic factors such as IGF-1, leptin, growth factors and androgens. An understanding of these associations may shed new light on the etiology of prostate cancer among all men.
